Recent studies from Norway have demonstrated the effectiveness of COVID-19 vaccinations in reducing the risk of long COVID by approximately 40% and associated cardiovascular and thrombotic events in the entire population of about 5.4 million people. The comprehensive analysis, published in the Lancet Respiratory Medicine, highlights a significant decrease in the incidence of long COVID symptoms among vaccinated individuals. Specific findings reveal varying standardized hazard ratios (sHRs) for long COVID symptoms prevention, including 0.54 in CPRD GOLD, 0.48 in CPRD AURUM, 0.71 in SIDIAP, and 0.59 in CORIVA. These results underscore the vaccines' role in mitigating not only the immediate impacts of COVID-19 but also its prolonged health complications.
High frequencies of alpha cc coV/SARSCoV2 cross-reactive functional CD4+ & CD8+ mTcells are asso with protection from symptomatic, fatal SARSCoV2 infections in unvac COVID19; Compared to severely ill COVID19 & fatal COVID19 outcomes- asymptomatic COVID19 https://t.co/zdcsU5Wc9R
Nirmatrelvir plus ritonavir reduced the risk of Covid-19–related hospitalization or death in unvaccinated, high-risk adults, but whether it can reduce symptom duration in a broader group is unknown. Watch a Quick Take video on the research findings: https://t.co/cgMUK1wwIk
Effectiveness of COVID-19 vaccines to prevent long COVID: data from Norway More evidence that immunity significantly reduces the risk of #LongCovid, thromboembolic and cardiovascular complications. https://t.co/109vYEs46k 1/2 https://t.co/4QIH8LbpJ5
Effectiveness of COVID19 vac to prevent long COVID: data from Norway; Lancet Respiratory Medicine: vac consistently prevent LC symptoms in adults, (sHRs) of 0·54 in CPRD GOLD, 0·48 in CPRD AURUM, 0·71 in SIDIAP, 0·59 in CORIVA. https://t.co/hT6KdO3bJq
Vaccination reduced the risk of #LongCovid by ~40% in the entire population (5.4 million) of Norway https://t.co/pwVRT1fhh8 and reduced cardiovascular and thrombotic events @NhungPharma @LancetRespirMed https://t.co/DD1qAUKB2L